Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,096 shares of the life sciences company’s stock after acquiring an additional 177 shares during the quarter. GAMMA Investing LLC’s holdings in Illumina were worth $414,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of ILMN. Victory Capital Management Inc. grew its position in Illumina by 5.9% in the 2nd quarter. Victory Capital Management Inc. now owns 134,094 shares of the life sciences company’s stock valued at $13,997,000 after buying an additional 7,527 shares in the last quarter. Private Advisor Group LLC boosted its holdings in shares of Illumina by 122.5% in the second quarter. Private Advisor Group LLC now owns 11,025 shares of the life sciences company’s stock valued at $1,152,000 after acquiring an additional 6,070 shares in the last quarter. Candriam S.C.A. increased its stake in shares of Illumina by 8.6% during the second quarter. Candriam S.C.A. now owns 205,043 shares of the life sciences company’s stock valued at $21,401,000 after acquiring an additional 16,283 shares during the period. New Mexico Educational Retirement Board raised its holdings in Illumina by 306.3% during the second quarter. New Mexico Educational Retirement Board now owns 32,300 shares of the life sciences company’s stock worth $3,371,000 after purchasing an additional 24,350 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in Illumina in the second quarter worth approximately $466,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ILMN. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Thursday, October 17th. Leerink Partners lifted their target price on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Piper Sandler lowered their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, Stephens increased their target price on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $165.95.

Illumina Stock Up 3.9 %

Illumina stock opened at $136.01 on Monday. Illumina, Inc. has a twelve month low of $100.08 and a twelve month high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The firm has a market cap of $21.57 billion, a PE ratio of -13.66 and a beta of 1.11. The firm’s 50 day moving average price is $141.86 and its two-hundred day moving average price is $131.55.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.33 earnings per share. On average, research analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.